Cellectis S.A. · EURONEXT:ALCLS
Cellectis — Investor Presentation (November 2020)
18 slides from Cellectis's investor presentation, Nov 6, 2020
Slide 1: Commitment to a Cure
COMMITMENT TO A CURE cellectis.co m
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation contains “forward-looking” statements that the risk that any one or more of our product candidates will are based on our management’s current expectations and not be successfully developed and commercialized. assumptions and on information currently avail
Slide 3: Writing the History of Allogeneic CAR T-Cells
WRITING THE HISTORY OF ALLOGENEIC CAR T-CELLS 20 years 8 years 6 clinical trials of expertise in of experience in allogeneic ongoing as of 2020; gene editing CAR-T manufacturing 3 Cellectis-sponsored 3 partnered INVENTORS / PIONEERS OF GENE EDITING & ALLOGENEIC CAR T-CELLS In 2012 . . In 2015 . . Mi
Slide 4: Advantages of Allogeneic vs. Autologous CAR-T
ADVANTAGES OF ALLOGENEIC VS. AUTOLOGOUS CAR-T Autologous process: Manufacturing variability + several weeks before treatment is available 1. 2. 3. 4. CANCER TREATMENT CANCER MANUFACTURING INDIVIDUAL CAR-T DECISION PATIENT APHERESIS OF A SINGLE THERAPY PATIENT PRODUCT Allogeneic process: Consistent m
Slide 5: Partnerships with Industry Leaders
PARTNERSHIPS WITH INDUSTRY LEADERS Up to $3.2B in potential milestone payments plus royalties Partner License Geography Most Advanced Status Economics to Targets Cellectis Exclusive license to CD19- UCART19 Up To $410M In Ex-US Ph1 directed allogeneic CAR T-Cells (Anti-CD19) Development & Sales Mile
Slide 6: Pipeline: Innovative Cancer Therapies for Unmet Needs
PIPELINE: INNOVATIVE CANCER THERAPIES FOR UNMET NEEDS Product Disease Study Phase 1 Phase 1 Pivotal Phase 2 Dose Escalation Dose Expansion ACUTE MYELOID UCART123 AMELI-01 LEUKEMIA ACUTE UCART22 LYMPHOBLASTIC BALLI-01 LEUKEMIA MULTIPLE UCARTCS1 MELANI-01 ON CLINICAL HOLD MYELOMA ACUTE UCART19 3 LYMPH
Slide 7: Clinical Trial: Design of Phase 1 Dose Escalation Studies
CLINICAL TRIAL: DESIGN OF PHASE 1 DOSE ESCALATION STUDIES Primary Objectives: Secondary Objectives: Safety and Identification Efficacy and Correlative of Optimal Dose Studies Dose Escalation: Optimal dose definition DL1 DL2 DL3 DL4 2-4 patients 2-4 patients 2-4 patients 2-4 patients DL: Dose Level *
Slide 8: ALLO-501: Cellectis Licensed Allogeneic CAR-T
ALLO-501*: CELLECTIS LICENSED ALLOGENEIC CAR-T PHASE 1 dose escalation N=22 (safety) in R/R Non-Hodgkin N=19 (efficacy) Lymphoma ALPHA Study Safety – Primary Objective Efficacy – Secondary Objective 0% Graft vs Host Disease 63% Overall Response Rate 0% ICANS (Immune Effector Cell-Associated 37% Comp
Slide 9: UCART123 in Acute Myeloid Leukemia
UCART123 IN ACUTE MYELOID LEUKEMIA AML Incidence Rates & Survival Data 19,940 27% 6% Estimated new cases of AML in the US for 2020 5-year OS in adults 5-year OS in adults >55 years old High CD123 expression on malignant cells Limited CD123 expression on healthy cells CD123 is expressed >90% on malig
Slide 10: UCART22 in Acute Lymphoblastic Leukemia
UCART22 IN ACUTE LYMPHOBLASTIC LEUKEMIA ALL Incidence Rates & Survival Data 6,150 20% <6 Estimated new cases of ALL in 5-year OS in adults Months median disease-free survival the US for 2020 in R/R pediatric patients CD22 Expression in B-cells Treatment potential for CD19-negative patients Flow cyto
Slide 11: UCARTCS1 in Multiple Myeloma
UCARTCS1 IN MULTIPLE MYELOMA MM Incidence Rates & Survival Data 32,270 43-83 50% Estimated new cases of MM in the US for 2020 Months is median OS for stages 2-3 5-year OS in adults High expression on malignant cells Treatment alternative to BCMA-targeted therapies >95% Many BCMA-targeted cell therap
Slide 12: UCARTs – Allogeneic CAR T-Cells Through Precision Gene Editing
UCARTs – ALLOGENEIC CAR T-CELLS THROUGH PRECISION GENE EDITING RATIONAL Engineering EFFECTIVE via accurate insertion of Persistence best CAR via knock-out of CD52 or b2-microglobulin UCART Universal Chimeric Antigen Receptor T-cell TUMOR CELL SMART SAFE Action Administration CAR linked to suicide sw
Slide 13: TALEN Gene Editing – Advantages
TALEN® GENE EDITING – ADVANTAGES TALEN®: Driven by protein/DNA interactions to work on potential off- Our nucleases act like DNA scissors to edit genes at precise target sites: site cleavage + Releases DNA ends accessible to DNA repair mechanisms to DNA sequence perform gene insertions and correction
Slide 14: UCART Manufacturing
UCART MANUFACTURING Frozen Thawed PBMCs Lentivector TALEN®-mediated gene leukopaks transduction editing 8 years of experience in allogeneic CAR-T 1 2 3 4 manufacturing Validated gene editing technology for cell manufacturing 4 UCART product candidates manufactured so far Cell expansion Purification
Slide 15: In-House Manufacturing
IN-HOUSE MANUFACTURING Raw materials Clinical & Commercial UCART Product Candidates Paris, France Raleigh, NC 14,000 sq ft. facility 82,000 sq ft. facility Production of clinical Operational “go-live” Production of clinical & Operational "go-live" starting materials targeted in 2020 commercial UCART
Slide 16: The Cellectis Group
THE CELLECTIS GROUP ~64.7%* ownership NASDAQ: CLLS NASDAQ: CLXT EURONEXT GROWTH: ALCLS $30M cash as of September 30, 2020 (before the $15M Registered Direct Offering in October 2020) ~$278M** cash as of September 30, 2020 Cash Runway Extended into the Second Half of 2022 Expected to fund operations
Slide 17: Milestones
MILESTONES Proprietary clinical programs Partnered clinical programs Manufacturing UCARTCS1: Phase 1 R/R MM - currently on UCART191: Phase 1 in R/R ALL near 2 in-house GMP manufacturing plants: clinical hold; first patient dosed in Q4 completion 2019 Construction completed for Facility in Paris, ALL
Slide 18: Thank You
THANK YOU Reach us at: investor@cellectis.com Cellectis Paris Cellectis New York Cellectis Raleigh 8, rue de la Croix Jarry 430 East 29th Street 2500 Sumner Boulevard 75013 Paris – France 10016 New York, NY – USA 27616 Raleigh, NC – USA